- Datum27.08.2026
- Uhrzeit17:00 - 17:30 Uhr
- Veranstalter
stock3
Shanghai Haohai Biol.Te.Co.Ltd Chart inkl. Chartanalyse

Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen

Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Stuttgart | VK | |||||
| LS Exchange | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Wertentwicklung (L&S)
Passender Service zu Shanghai Haohai Biol.Te.Co.Ltd
Webinar zu Shanghai Haohai Biol.Te.Co.Ltd
Kursinformationen (L&S)
- Tagestief / Hoch (€)-
- 52W-Tief / Hoch (€)1,130-3,300
- Jahrestief / Hoch (€)1,130-2,920
- Schlusskurs (Vortag)
- Eröffnungskurs
Wichtigste Eigenschaften
Dividenden von Shanghai Haohai Biol.Te.Co.Ltd
Termine von Shanghai Haohai Biol.Te.Co.Ltd
- Aug22Shanghai Haohai Biol.Te.Co.LtdQ2 2026 Earnings Release
- Okt23Shanghai Haohai Biol.Te.Co.LtdQ3 2026 Earnings Release
- Mär22Shanghai Haohai Biol.Te.Co.LtdQ4 2026 Earnings Release
Beschreibung
Shanghai Haohai Biological Technology Co., Ltd. is a global enterprise dedicated to the research, development, manufacturing, and commercialization of biomedical materials. Its operations span Mainland China, the United States, the United Kingdom, and various other international regions. A comprehensive product portfolio addresses several key medical disciplines. Within ophthalmology, offerings include intraocular lenses, ophthalmic viscoelastic devices, orthokeratology and phakic refractive lenses, eye drops, injectors, and surgical scalpels. Orthopedics products encompass sodium hyaluronate injections and medical chitosan. For wound repair, it manufactures recombinant human epidermal growth factor, effective in treating burn wounds, residual wounds, donor site post-traumatic wounds, and both fresh and chronic ulcerations. Additionally, the company develops anti-adhesion materials, including medical sodium hyaluronate gel and medical chitosan, as well as hemostatic solutions such as collagen sponges and porcine fibrin sealants. Beyond its therapeutic offerings, Shanghai Haohai maintains a significant presence in the medical aesthetics market. This segment features a range of hyaluronic acid (HA) dermal fillers: Matrifill, positioned as a first-generation mono-phase injectable HA gel; Janlane, a second-generation filler engineered for dynamic application; and Hyalumatrix, a third-generation product providing precise aesthetic embellishment. Its aesthetic portfolio is further complemented by radio frequency devices and laser equipment. Furthermore, the company actively engages in the research and development of biological engineering and pharmaceutical products, extending services such as technology transfer and consultation. It also conducts investment and trading operations. Established in 2007, the entity initially traded as Haohai Limited before officially adopting the name Shanghai Haohai Biological Technology Co., Ltd. in 2010. Its corporate headquarters are based in Shanghai, China.
